...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone

Free
Message: What if

The aminotransferase story is more complex than just handwaving it away as a mild, transient issue due to plaque clearing by the liver. There may be some interplay with FXR and bile acid metabolism too. I highly recommend you check out this past post entitled "FXR and liver transaminase related adverse events".

Also from the 2015 AGM (transcript courtesy of imtesty):

"We think we’re getting to the bottom of this adverse event. We’ve done a lot of work in the laboratory to investigate this. And we seem to see that there is a change in bile acid metabolism in selected patients, because BET inhibition does change the expression of bile transporters and bile enzymes in selected individuals. So there’s an increase in influx of cholesterol, and a change in bile pathway, and a down regulation, transient. But this down-regulation does not persist for long; there is an adaption within the liver cell, which accounts for why the enzyme levels go away with continued therapy. The net effect is an increase in bile acids in a very small number of patients. And we’re working in the lab to confirm this hypothesis. One of the reasons behind our BETonMACE study, apart from outcomes, is to get a very large safety database, to truly document the incidence and the consequences of these hepatic enzyme increases."

For more detail on the elevated ALT/AST data from the ASSURE study, see this document, which throughly documents adverse events and ALT/AST values from ASSURE. 

A summary of the ALT/AST observations in ASSURE is below (RVX000222=apabetalone):

"There were no clinically significant observations in laboratory results, with the exception of ALT/AST elevations, which occurred more frequently in the RVX000222 group compared with placebo (42.0% vs. 22.5%, p=0.002). In the RVX000222 group, 7.0% (17/243) had ALT elevations >3x ULN; among patients with any ALT elevation, 9.3% (9/97) had elevations >5x ULN. In the RVX000222 group, 4.1% (10/243) had AST elevations >3x ULN; among patients with any AST elevation, 7.0% (5/71) had elevations >5x ULN."

If history repeats itself, and if the same criteria in ASSURE are used in BETonMACE, one should expect some patients in the apabetalone group to be forced to discontinue due to sustained elevations of ALT or AST above 5X the upper limit of normal (ULN) or exceeding 8X the ULN at any one time.Those elevations below 5X ULN were acceptable in ASSURE, but two consecutive measures above 5X ULN or one single measurement above 8X ULN resulting in patient discontinuation.

BearDownAZ

 

 

 

Share
New Message
Please login to post a reply